Targeting KRAS4A splicing through the RBM39/DCAF15 pathway inhibits cancer stem cells
Open Access
- 13 July 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Communications
- Vol. 12 (1), 1-14
- https://doi.org/10.1038/s41467-021-24498-7
Abstract
The commonly mutated human KRAS oncogene encodes two distinct KRAS4A and KRAS4B proteins generated by differential splicing. We demonstrate here that coordinated regulation of both isoforms through control of splicing is essential for development of Kras mutant tumors. The minor KRAS4A isoform is enriched in cancer stem-like cells, where it responds to hypoxia, while the major KRAS4B is induced by ER stress. KRAS4A splicing is controlled by the DCAF15/RBM39 pathway, and deletion of KRAS4A or pharmacological inhibition of RBM39 using Indisulam leads to inhibition of cancer stem cells. Our data identify existing clinical drugs that target KRAS4A splicing, and suggest that levels of the minor KRAS4A isoform in human tumors can be a biomarker of sensitivity to some existing cancer therapeutics.This publication has 45 references indexed in Scilit:
- Comprehensive molecular characterization of human colon and rectal cancerNature, 2012
- A MEK-independent role for CRAF in mitosis and tumor progressionNature Medicine, 2011
- Exploiting Cancer Cell Vulnerabilities to Develop a Combination Therapy for Ras-Driven TumorsCancer Cell, 2011
- Reducing MCM levels in human primary T cells during the G0→G1 transition causes genomic instability during the first cell cycleOncogene, 2010
- Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRβ/B-RAFProceedings of the National Academy of Sciences of the United States of America, 2010
- p53 Regulates Hematopoietic Stem Cell QuiescenceCell Stem Cell, 2009
- The Biflavonoid Isoginkgetin Is a General Inhibitor of Pre-mRNA Splicing*Online Journal of Public Health Informatics, 2008
- Kras regulatory elements and exon 4A determine mutation specificity in lung cancerNature Genetics, 2008
- Tumour stem cells and drug resistanceNature Reviews Cancer, 2005
- While K-ras Is Essential for MouseDevelopment, Expression of the K-ras 4A Splice VariantIsDispensableMolecular and Cellular Biology, 2003